Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 100,000 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 100,000 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $11.28, for a total value of $1,128,000.00. Following the completion of the sale, the chief operating officer now owns 732,294 shares of the company’s stock, valued at approximately $8,260,276.32. This represents a 12.01 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Eric Venker also recently made the following trade(s):

• On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The shares were sold at an average price of $11.54, for a total value of $2,050,704.16.
• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The shares were sold at an average price of $11.82, for a total value of $2,090,958.00.
• On Friday, December 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.49, for a total value of $1,149,000.00.
• On Wednesday, November 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.32, for a total transaction of $1,132,000.00.

Roivant Sciences Price Performance

Shares of ROIV stock opened at $11.17 on Friday. The firm has a 50-day moving average of $11.74 and a 200-day moving average of $11.60. Roivant Sciences Ltd. has a one year low of $9.69 and a one year high of $13.06. The company has a market cap of $8.13 billion, a P/E ratio of 1.98 and a beta of 1.27.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $17.93.

Institutional Investors Weigh In On Roivant Sciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in ROIV. Mutual of America Capital Management LLC grew its holdings in shares of Roivant Sciences by 0.4% in the second quarter. Mutual of America Capital Management LLC now owns 327,079 shares of the company’s stock valued at $3,457,000 after acquiring an additional 1,142 shares in the last quarter. GAMMA Investing LLC boosted its position in Roivant Sciences by 57.0% in the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after purchasing an additional 1,288 shares during the last quarter. Covestor Ltd grew its stake in Roivant Sciences by 9.1% in the 3rd quarter. Covestor Ltd now owns 19,190 shares of the company’s stock valued at $222,000 after purchasing an additional 1,605 shares during the period. US Bancorp DE increased its position in shares of Roivant Sciences by 146.5% during the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock valued at $38,000 after purchasing an additional 1,948 shares during the last quarter. Finally, Quarry LP raised its stake in shares of Roivant Sciences by 50.0% during the 3rd quarter. Quarry LP now owns 7,500 shares of the company’s stock worth $87,000 after purchasing an additional 2,500 shares during the period. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.